{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Specified adverse events are defined as any treatment-related adverse events that are grade 4, grade 5, or any of the following treatment-related grade 3 adverse events:\n\n* Gastrointestinal: dysphagia, esophagitis, esophageal stricture, esophageal ulceration;\n* Cardiac: pericarditis, pericardial effusion, cardiomyopathy, ventricular dysfunction;\n* Neurologic: myelitis, neuropathy (cranial and motor)\n* Hemorrhage: pulmonary or upper respiratory\n* Pulmonary: decline in pulmonary function as measured by pulmonary function tests, pneumonitis, pulmonary fibrosis, hypoxemia, pleural effusion.\n\nAdverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The Common Terminology Criteria for Adverse Events (CTCAE) v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.","groups":[{"description":"20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy stereotactic body radiation therapy","id":"OG000","title":"Stereotactic Body Radiation Therapy (SBRT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Analysis occurred after all patients had been on study for at least 2 years. Maximum follow-up at time of analysis was 4.2 years.","title":"Proportion of Subjects With Specified Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}